I agree Supertramp. PWN have several ways they can look at funding projects as well as possible partners and major shareholders who may help. One method often used in the larger projects is progress payments which tends to break the working capital requirements down to much smaller values. The risk vs reward here is definitely improving consistently despite the languishing SP. Also good to see you are still here and on some of those promising biotechs too.
I agree Supertramp. PWN have several ways they can look at...
Add PWN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
-0.001(11.1%) |
Mkt cap ! $20.10M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.9¢ | 0.8¢ | $27.29K | 3.336M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 8382320 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 4962304 | 7 |
View Market Depth
| Last trade - 15.24pm 16/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.8¢ |
Change
-0.001 ( 11.1 %) |
||||
| Open | High | Low | Volume | ||
| 0.9¢ | 0.9¢ | 0.8¢ | 327519 | ||
| Last updated 15.54pm 16/05/2024 ? | |||||
| PWN (ASX) Chart |